Peers, clients, partners and colleagues gathered for the grand opening of the new FutureMeds Wroclaw Dedicated Research Site and the Regional HQ at a state-of-the-art Class A building in the heart of Wroclaw, Poland.
As part of setting the stage for further growth and progress, on the 5th of December, FutureMeds officially opened its new Wroclaw Dedicated Research Site and Regional HQ. Besides representing the culmination of 4 years of progress, the ceremony marked a new chapter in the Site Network’s history.
FutureMeds’ clinical research journey started in 2019 with a small research site in Wroclaw, about 2.5km from the new location. After four years, FutureMeds has evolved into Europe's 1st Independent Dedicated DCT Site Network, operating DRSs in six countries. Earlier this year, the company launched its DCT solution, FutureMeds @home, which is now available in 18 European countries.
“Today's event marks the end of our initial growth phase that saw us grow from 1 dedicated research site to 19 across 6 countries and propelled us among the top-performing site networks in Europe. The old Wroclaw site, the first to screen patients for a FutureMeds study, is now closing its doors. Our experienced team, which grew from 3 to 60, are moving into a state-of-the-art facility.”
- Dr Radosław Janiak, CEO of FutureMeds
"My compliments to Monika Paradyz, our site director, and the whole team for leading with example and delivering over 50 studies since the early days of our company. We enter the next chapter of our journey with increased commitment to bringing future therapies to Poland and abroad," added Dr Radoslaw Janiak.
At the grand opening, the FutureMeds team was honoured to welcome representatives of GSK, Amgen, Fortrea, IQVIA, and Parexel, delegates of local partners, organisations, healthcare practitioners, and vendors who played key roles in the site network’s progress.
To support Awangarda, a self-funded Polish organisation of frontline medics that operates in Ukraine’s Donbas area, FutureMeds welcomed another group of special guests, Katarzyna Daniszewska, commander of the Awangarda and her team, who shared insights into the realities and life-saving work their team does to assist the Armed Forces of Ukraine in evacuating and treating soldiers and civilians who require medical attention.
Following the presentations and office and clinic tours, the esteemed guests and the FutureMeds team proceeded to Hotel Altus Palace for dinner, where they exchanged views on the promising prospects of the clinical trial market in Poland.
FutureMeds Wroclaw’s A New Chapter
FutureMeds Wroclaw DRS team started moving operations to the new location at the end of September and welcomed the first volunteer on the 9th of October.
The new Dedicated Research Site’s advanced medical suite is situated on the ground floor of the seven-story Class A office space, which boasts an Excellent BREEAM certificate rating and the WELL Health-Safety certificate, underscoring its quality and sustainability.
The advanced medical suite features 7 medical rooms, 6 nursing rooms, and a local lab. It also includes dedicated spaces for patient observation, post-IMP administration and storage solutions for laboratory kits and IMP.
“We are convinced that the new location, along with all its advantages, will give the citizens of Wroclaw and patients in the surrounding area even faster access to new therapeutic options as part of clinical trials conducted at FutureMeds.”
- Monika Paradyż, Site Director of FutureMeds Wroclaw.
The 1st floor, where the HQ is located, houses the administrative areas. It has an open office space for data coordinators and administrative staff, secure rooms for patient record storage, 4 medical monitor rooms, and a conference room.
Connecting with Local Heritage
Celebrating Wroclaw's culture, FutureMeds has commissioned a unique bronze dwarf figurine named Futurek, designed by renowned local sculptor Arkadiusz Kusz. Located near the new site, the 30 cm tall figurine symbolises FutureMeds' connection to the local tradition and dedication to the Wroclaw community and patient population.
Dwarf figurines are a famous symbol of Wroclaw; visitors and citizens can find about 300 of them scattered all over the city.
Poland: a growing clinical trial powerhouse
Establishing a Regional HQ in Poland is central to FutureMeds’ growth plans, and our teams are committed to strengthening our presence in the country and the Central and Eastern European region, creating more employment opportunities, developing our Dedicated Research Site network and increasing the valuable scientific contribution both locally and globally.
Compared to the more established markets, Poland and Central and Eastern Europe offer higher site productivity, lower costs & trial set-up costs and a solid quality reputation. A strong presence in Poland will enable FutureMeds to deliver greater value to clients and help a growing European patient population gain access to cutting-edge treatments.
Poland has been propelled into an innovative biopharmaceutical industry clinical trials (iBPCTs) powerhouse status by the country’s centralised healthcare system, motivated investigators, large patient population and comparatively low costs.
According to the Industry Clinical Trials in Poland 2021 report, Poland ranked 11th globally in terms of iBPCT market share in 2019. During the 2014-2019 period, the country posted the 5th largest iBPCT market share gain globally, behind China, Spain, South Korea and Taiwan, whose economic value of iBPCTs represented more than USD 1.3 billion.
Specialising in conducting clinical trials, FutureMeds is the 1st European Independent Dedicated DCT Site Network offering high levels of traditional and Decentralized Clinical Trial capabilities across the whole network and home nursing solutions in 18 European countries.
FutureMeds is driven by a purpose to connect a global healthcare community and help bring quicker access to life-changing medications and therapies to all those who need them worldwide.
FutureMeds’ Dedicated Research Site (DRS) teams serve as the company's service foundation. DRS team’s execution capabilities help pharmaceutical companies and contract research organisations accelerate study timelines, streamline processes, lower costs, improve data quality and ultimately help speed up drug development and patient access to new treatments.
FutureMeds @home, the company’s Decentralized Clinical Trial solution, provides pharmaceutical companies, contract research organisations and other partners with powerful insights, tools, teams & support, enabling them to simplify patient access to trials and boost recruitment, engagement and retention.
Through its acquisitions, partnerships and a strategic focus on patient experience, FutureMeds brings opportunities to diverse European patient populations to participate in clinical research under the medical supervision of qualified physicians and health care professionals.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.